During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.
There are three UC-approved biologics in Canada, which are the TNF inhibitors, Remicade, Humira and Simponi. Remicade has the larger potential patient pool, as it was approved for use in UC patients long before Humira (in 2013), which was only approved for UC in 2013. It can also be used either alone or in combination with conventional therapy. This, together with its high annual cost of therapy, means that Remicade experiences strong uptake in the Canadian UC market, which positions it as the market-leading therapy.
http://beforeitsnews.com/business/2014/04/canada-ulcerative-colitis-drug-market-analysis-to-2022-2622784.html